169 results on '"Wen, Patrick Y"'
Search Results
2. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group.
3. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.
4. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
5. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
6. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
7. Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.
8. Systematic characterization of antibody–drug conjugate targets in central nervous system tumors.
9. Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.
10. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma.
11. A genomic score to predict local control among patients with brain metastases managed with radiation.
12. RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
13. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.
14. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
15. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
16. Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity.
17. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
18. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries.
19. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients.
20. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
21. Evaluating hematologic parameters in newly diagnosed and recurrent glioblastoma: Prognostic utility and clinical trial implications of myelosuppression.
22. An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma.
23. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors.
24. Investigational PET tracers in neuro-oncology—What's on the horizon? A report of the PET/RANO group.
25. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
26. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications.
27. Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.
28. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib.
29. molecularly integrated grade for meningioma.
30. Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis.
31. Negative trials over and over again: How can we do better?
32. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
33. use of external control data for predictions and futility interim analyses in clinical trials.
34. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.
35. Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
36. Telomerase as a therapeutic target in glioblastoma.
37. Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
38. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
39. Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis.
40. Epidemiology of brain metastases and leptomeningeal disease.
41. Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology.
42. Population-based estimates of survival among elderly patients with brain metastases.
43. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
44. Predictors of long-term survival among patients with brain metastases.
45. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
46. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
47. Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.
48. Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
49. Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
50. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.